Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis

This publication has 12 references indexed in Scilit:

• Clinical Presentation and Results of Thrombolytic Therapy in Older Patients with Massive Pulmonary Embolism: A Comparison with Non‐Elderly Patients
  Journal of the American Geriatrics Society, 1996
• Reduced Dose Bolus Alteplase vs Conventional Alteplase Infusion for Pulmonary Embolism Thrombolysis
  Chest, 1994
• Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: A comparison with nonelderly patients
  Journal of the American College of Cardiology, 1993
• Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion
  The Lancet, 1993
• Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial
  Journal of the American College of Cardiology, 1992
• The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: Results from thrombolysis in myocardial infarction phase I, open label studies and the thrombolysis in myocardial infarction phase II pilot study
  Journal of the American College of Cardiology, 1989
• RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM
  The Lancet, 1988
• Thrombolytic therapy of acute pulmonary embolism: Current status and future potential
  Journal of the American College of Cardiology, 1987
• Perspectives on Treatment of Acute Pulmonary Embolism with Tissue Plasminogen Activator
  Seminars in Thrombosis and Hemostasis, 1987
• ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATOR
  The Lancet, 1986